BIOGEN PLANS TO INITIATE PHASE 4 STUDY EVALUATING BENEFIT OF SPINRAZA® (NUSINERSEN) IN PATIENTS TREATED WITH ZOLGENSMA® (ONASEMNOGENE ABEPARVOVEC)
Today, Pharmaceutical Company – Biogen Inc, announced that plans to initiate clinical trial, named RESPOND, phase 4, to evaluate the benefit and safety of SPINRAZA® (NUSINERSEN) in infants up to 9 months and children up to 3 years treated with ZOLENSMA ® (ONASEMNOGENE ABEPARVOVEC)(60 partcipants in total). The company intends to submit the study protocol to the regulatory authorities in the coming months and aims for the first eligible patients to be enrolled in the RESPOND study in Q1 2021.
For more information read the Company’s Press Release: